CIK 0001652130 · Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364785571
- Phone
- 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- 8-K Event Regulation FD disclosure · Other events
- 8-K Event Regulation FD disclosure · Other events
- 4 Open-market sale President and CEO sold 34,146 shares at $9.21 ($314,485)
- 4 Open-market sale EVP, Chief Scientific Officer sold 8,508 shares at $9.21 ($78,359)
- 4 Open-market sale EVP, General Counsel sold 10,397 shares at $9.21 ($95,756)
- 4 Open-market buy Director bought 150,000 shares at $9.35 ($1,402,500)
- 4 Open-market sale EVP, Chief Medical Officer sold 11,903 shares at $9.21 ($109,627)
- 4 Open-market sale EVP, Chief Technical Officer sold 9,515 shares at $9.21 ($87,633)
- 4 Open-market sale EVP, Chief Financial Officer sold 6,379 shares at $9.21 ($58,751)
- 4 Open-market sale VP, Chief Accounting Officer sold 2,989 shares at $9.21 ($27,529)
- 4 Planned sale President and CEO sold 88,146 shares at an average $9.49 ($836,384)
- 144 Insider Sale of Securities
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 8-K Event Regulation FD disclosure · Other events
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 8-K Event Other events
- 8-K Event Regulation FD disclosure · Other events
Page 4 of 37 · 725 filings